サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1722789

単純ヘルペスウイルス治療市場レポート、規模、シェア、動向、予測：タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025年～2033年

Herpes Simplex Virus Treatment Market Report Size, Share, Trends and Forecast by Type, Drug Type, Route of Administration, Distribution Channel, and Region, 2025-2033

出版日
発行
IMARC
ページ情報
英文 134 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
単純ヘルペスウイルス治療市場レポート、規模、シェア、動向、予測：タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025年～2033年
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 134 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

単純ヘルペスウイルス治療の世界市場規模は2024年に27億米ドルとなりました。今後、IMARC Groupは、市場は2033年までに40億米ドルに達し、2025年から2033年にかけて4.51%のCAGRを示すと予測しています。現在、北米が市場を独占しています。HSVの様々な治療薬に関する個人の意識の高まり、ヘルスケア支出の増加、オンラインおよびオフラインの薬局店を通じてHSV治療薬が広く入手可能であることが、市場を牽引する主な要因のいくつかです。

単純ヘルペスウイルス（HSV）は、唾液、精液、膣分泌液を介して感染し、水疱や潰瘍を引き起こす伝染性のウイルス感染症を指します。個人間で単純ヘルペスウイルス-1（HSV-1）感染と単純ヘルペスウイルス-2（HSV-2）感染を起こします。また、ただれができる前に、発熱、体の痛み、リンパ節の腫れ、頭痛、口の周りのヒリヒリ感、かゆみ、灼熱感などを引き起こします。通常、HSVの性的パートナーがいる人や免疫不全の人に発症します。HSVはアシクロビル、ファムシクロビル、バラシクロビルなどの抗ウイルス薬を服用することで治癒します。また、温湿布や冷湿布、アロエベラ、重曹やコーンスターチと水を混ぜたペースト、潰したニンニクを混ぜたものなど、いくつかの家庭療法によって治療することもできます。HSVの治療は、ウイルスを感染させる確率を下げ、発症の頻度や重症度を減らすのに役立ちます。

単純ヘルペスウイルス治療市場動向：

現在、世界中の大衆の間で性感染症（STI）の有病率が上昇していることは、市場の成長を支える重要な要因の一つです。加えて、世界中の個人の性的健康に対する懸念からHSV治療に対する需要が増加していることも、市場の成長を後押ししています。これに加えて、世界中でHSV感染のリスクと合併症に関する個人の意識が高まっているため、HSV治療に対する需要が増加しており、市場にプラスの影響を与えています。さらに、副作用を軽減し、有効性を高めた新しいHSV治療オプションに対する需要の高まりが、市場の成長を促進しています。これとは別に、医療費の増加は、個人の所得水準の上昇とともに、業界の投資家に有利な成長機会を提供しています。さらに、世界中のオンラインおよびオフラインの薬局でHSV治療薬が広く入手可能であることも、市場の成長を後押ししています。これに加えて、脳炎（脳感染）や角膜炎（眼感染）のような重篤な合併症を予防するためのHSV治療オプションに対する需要の増加が、市場の成長に寄与しています。さらに、HSV治療オプションにおける技術革新の高まりと様々な医薬品承認が市場の成長を強化しています。

本レポートで扱う主な質問

  • 単純ヘルペスウイルス治療市場の規模は？
  • 単純ヘルペスウイルス治療市場の将来展望は？
  • 単純ヘルペスウイルス治療市場を牽引する主要因は何か？
  • 単純ヘルペスウイルス治療市場で最大のシェアを占める地域は？
  • 世界の単純ヘルペスウイルス治療市場における主要企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の単純ヘルペスウイルス治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 単純ヘルペスウイルス1型感染症
  • 単純ヘルペスウイルス2型感染症
  • その他

第7章 市場内訳：薬剤タイプ別

  • アシクロビル
  • バラシクロビル
  • ファムシクロビル
  • その他

第8章 市場内訳：投与経路別

  • 経口
  • 注射
  • 外用

第9章 市場内訳：流通チャネル別

  • 病院薬局
  • ドラッグストア
  • 小売店
  • オンライン薬局

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Agenus Inc.
    • Apotex Inc.
    • Avet Pharmaceuticals Inc.
    • Carlsbad Tech
    • EPI Health LLC
    • F. Hoffmann-La Roche Ltd
    • Fresenius SE & Co. KGaA
    • GlaxoSmithKline plc
    • Glenmark Pharmaceuticals Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
図表

List of Figures

  • Figure 1: Global: Herpes Simplex Virus Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Herpes Simplex Virus Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Herpes Simplex Virus Treatment Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Herpes Simplex Virus Treatment Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Herpes Simplex Virus Treatment Market: Breakup by Route of Administration (in %), 2024
  • Figure 7: Global: Herpes Simplex Virus Treatment Market: Breakup by Distribution Channel (in %), 2024
  • Figure 8: Global: Herpes Simplex Virus Treatment Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Herpes Simplex Virus Treatment (Herpes Simples Virus-1 Infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Herpes Simplex Virus Treatment (Herpes Simples Virus-1 Infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Herpes Simplex Virus Treatment (Herpes Simplex Virus-2 Infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Herpes Simplex Virus Treatment (Herpes Simplex Virus-2 Infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Herpes Simplex Virus Treatment (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Herpes Simplex Virus Treatment (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Herpes Simplex Virus Treatment (Acyclovir) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Herpes Simplex Virus Treatment (Acyclovir) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Herpes Simplex Virus Treatment (Valacyclovir) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Herpes Simplex Virus Treatment (Valacyclovir) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Herpes Simplex Virus Treatment (Famciclovir) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Herpes Simplex Virus Treatment (Famciclovir) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Herpes Simplex Virus Treatment (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Herpes Simplex Virus Treatment (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Herpes Simplex Virus Treatment (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Herpes Simplex Virus Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Herpes Simplex Virus Treatment (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Herpes Simplex Virus Treatment (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Herpes Simplex Virus Treatment (Topical) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Herpes Simplex Virus Treatment (Topical) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Herpes Simplex Virus Treatment (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Herpes Simplex Virus Treatment (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Herpes Simplex Virus Treatment (Drug Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Herpes Simplex Virus Treatment (Drug Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Herpes Simplex Virus Treatment (Retail Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Herpes Simplex Virus Treatment (Retail Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Herpes Simplex Virus Treatment (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Herpes Simplex Virus Treatment (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: North America: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: North America: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: United States: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: United States: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Canada: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Canada: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Asia-Pacific: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Asia-Pacific: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: China: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: China: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Japan: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Japan: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: India: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: India: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: South Korea: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: South Korea: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Australia: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Australia: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Indonesia: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Indonesia: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Others: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Others: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Europe: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Europe: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Germany: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Germany: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: France: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: France: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: United Kingdom: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: United Kingdom: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Italy: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Italy: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Spain: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Spain: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Russia: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Russia: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Latin America: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Latin America: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Brazil: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Brazil: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Mexico: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Mexico: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Middle East and Africa: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Middle East and Africa: Herpes Simplex Virus Treatment Market: Breakup by Country (in %), 2024
  • Figure 85: Middle East and Africa: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Global: Herpes Simplex Virus Treatment Industry: SWOT Analysis
  • Figure 87: Global: Herpes Simplex Virus Treatment Industry: Value Chain Analysis
  • Figure 88: Global: Herpes Simplex Virus Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Herpes Simplex Virus Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Herpes Simplex Virus Treatment Market: Competitive Structure
  • Table 8: Global: Herpes Simplex Virus Treatment Market: Key Players
目次
Product Code: SR112025A5257

The global herpes simplex virus treatment market size was valued at USD 2.7 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 4.0 Billion by 2033, exhibiting a CAGR of 4.51% during 2025-2033. North America currently dominates the market. The growing awareness among individuals about various medications of HSV, increasing healthcare expenditure, and wide availability of HSV medications through online and offline pharmacy stores represent some of the key factors driving the market.

Herpes simplex virus (HSV) refers to a contagious viral infection that is spread through saliva, semen, and vaginal secretion and causes blisters and ulcers. It produces herpes simplex virus-1 (HSV-1) infection and herpes simplex virus-2 (HSV-2) infection among individuals. It also causes fever, body aches, swollen lymph nodes, headache, tingling, itching, or burning sensation around the mouth of an individual before the appearance of sores. It usually occurs among people having a sexual partner with HSV or who are immunocompromised. HSV can be cured by consuming some antiviral medications, such as acyclovir, famciclovir, and valacyclovir. It can also be treated through some home remedies, such as a warm or cold compress, aloe vera, a paste of baking soda or cornstarch and water, and a mixture of crushed garlic. HSV treatment can aid in lowering the chance of transmitting the virus and reducing the frequency or severity of outbreaks.

Herpes Simplex Virus Treatment Market Trends:

At present, the rising prevalence of sexually transmitted infections (STIs) among the masses around the world represents one of the key factors supporting the growth of the market. In addition, the increasing demand for HSV treatments due to concerns about sexual health among individuals worldwide is bolstering the growth of the market. Besides this, the growing demand for HSV treatments due to the increasing awareness among individuals about the risks and complications of HSV infection across the globe is positively influencing the market. Moreover, the rising demand for new HSV treatment options with reduced side effects and enhanced effectiveness is propelling the growth of the market. Apart from this, the increasing healthcare expenditure, along with the inflating income level of individuals, is offering lucrative growth opportunities to industry investors. Additionally, the wide availability of HSV medications through online and offline pharmacy stores across the globe is impelling the growth of the market. Besides this, the increasing demand for HSV treatment options to prevent severe complications, such as encephalitis (brain infection) or keratitis (eye infection) among individuals, is contributing to the growth of the market. Furthermore, the rising innovations in HSV treatment options and various drug approvals are strengthening the growth of the market.

Key Market Segmentation:

Type Insights:

  • Herpes Simples Virus-1 Infection
  • Herpes Simplex Virus-2 Infection
  • Others

Drug Type Insights:

  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Others

Route of Administration Insights:

  • Oral
  • Injectable
  • Topical

Distribution Channel Insights:

  • Hospital Pharmacy
  • Drug Stores
  • Retail Stores
  • Online Pharmacy

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for herpes simplex virus treatment. Some of the factors driving the North America herpes simplex virus treatment market included the growing prevalence of HSV infection among individuals, increasing number of clinical trials for its treatment, rising awareness about various medications of HSV, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global herpes simplex virus treatment market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Agenus Inc., Apotex Inc., Avet Pharmaceuticals Inc., Carlsbad Tech, EPI Health LLC, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1.How big is the herpes simplex virus treatment market?
  • 2.What is the future outlook of the herpes simplex virus treatment market?
  • 3.What are the key factors driving the herpes simplex virus treatment market?
  • 4.Which region accounts for the largest herpes simplex virus treatment market share?
  • 5.Which are the leading companies in the global herpes simplex virus treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Herpes Simplex Virus Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Herpes Simples Virus-1 Infection
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Herpes Simplex Virus-2 Infection
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Acyclovir
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Valacyclovir
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Famciclovir
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Topical
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacy
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Drug Stores
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Retail Stores
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Online Pharmacy
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agenus Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Apotex Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Avet Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Carlsbad Tech
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 EPI Health LLC
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Fresenius SE & Co. KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Glenmark Pharmaceuticals Limited
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Merck & Co. Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Novartis AG
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sanofi S.A.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Teva Pharmaceutical Industries Ltd.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Viatris Inc.
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials